Although cancer specialists remain deeply divided over the effectiveness of the PSA blood tests as a diagnostic tool for prostate cancer, some mathematical models projected that 45% to 70% of the observed decline in prostate cancer mortality could be plausibly attributed to the stage shift induced by PSA screening [7]. The gene discussed is KLK3; the disease is Familial prostate cancer.